Printer Friendly

Sankyo's Antihypertensive Agent, ARB Olmesartan to Be Available in Central and South America.

Tokyo, Japan, Aug 8, 2005 - (JCNN) - Sankyo announced on August 5 that it has signed a licensing agreement with Schering-Plough for its proprietary antihypertensive agent, olmesartan, an angiotensin II receptor blocker.

Under the terms of the agreement, Schering-Plough will exclusively sell the agent in Argentina, Boilvia, Chile, Paraguay, Peru and Uruguay.

In addition, Sankyo will allow Schering-Plough to co-market the agent in Costa Rica, the Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama and Venezuela.

Olmesartan is currently marketed in about 30 countries around the world.

Source: JCN http://www.japancorp.net

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Geographic Code:1USA
Date:Aug 9, 2005
Words:103
Previous Article:Ivy Cosmetics, Kitasato University Jointly Confirm That Shellac May Combat Skin Disorders.
Next Article:Nippon Organon to Release Recombinant Follicle Stimulating Hormone Follistim.
Topics:


Related Articles
FDA APPROVES BIOVAIL'S TEVETEN HCT FOR HYPERTENSION.
Sankyo Ceases Clinical Studies of Pactimibe, Investigational Drug for ASCVD.
Sankyo Announces Completion of Subject Registration for ORIENT Clinical Trial.
Sankyo Pharma GmbH to Transfer 11 Items to STADA Arzneimittel.
Daiichi Wins Lawsuit Against Mylan Pharmaceuticals Regarding Patents for Levofloxacin.
Sankyo Licenses Cardiovascular Disease Drug Candidate KAI-9803 from KAI Pharmaceuticals.
Daiichi Sankyo Now Authorized to Market Its Products in China.
Sankyo to Manufacture, Distribute Olmetic Antihypertensive Drug in China.
Daiichi Sankyo Subsidiary Applies for Additional Indication for Fentanyl Injection.
Daiichi Sankyo Files New Drug Application for Amoldipine Beslyte, Olmesartan Medoxomil Combination for Hypertension Treatment.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |